ACP: Clyde Yancy, MD, MSc Reviews Advances in Heart Failure Research and Treatment

April 29, 2021
Grace Halsey

ACP: Clyde W Yancy, MD, gave a comprehensive update on a year's worth of pivotal science in treatment of heart failure. Here are the highlights.

A presentation by Clyde Yancy, MD, MSc, is nearly always memorable – his eloquence, passion, and turn of phrase are worth an hour in a frigid hotel ballroom any time.

While his session today at the American College of Physicians Internal Medicine Meeting 2021: Virtual Experience was via Zoom, his review of the past 12-15 months of research in cardiology, and specifically in heart failure, was no less animated and his messages were clear:

  • Use the new HF diagnostic and risk scoring tools to identify at-risk patients and take action.
  • Optimize guideline recommended medical therapy for patients with heart failure.
  • Pay attention to evolving treatment options for HFpEF.
  • Be sure to review and understand the evidence that now substantiates the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) fore treatment of heart failure and comorbidities.

The slide show that follows is based on Dr Yancy's presentation and includes links to all of the primary studies that he discusses.


Clyde W. Yancy, MD, MSc, is Vice Dean of Diversity and Inclusion, Chief of Cardiology, Magerstadt Endowed Professor of Medicine Chair, and Professor of Medical Social Sciences at Northwestern University Feinberg School of Medicine; Associate Director of the Bluhm Cardiovascular Institute at Northwestern Memorial Hospital, Chicago, IL.